Tedizolid, sold under the brand name Sivextro is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It is rapidly converted in vivo to the active moiety by ubiquitous phosphatases and is formulated for intravenous and oral administration with high oral bioavailability. Tedizolid exhibits potent Gram positive activity including Staphylococcus aureus strains resistant to other agents; it inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, and its pharmacokinetic profile supports once-daily dosing and shorter approved treatment courses compared with earlier oxazolidinones. The molecule shows a favorable tissue penetration profile relevant to skin and soft tissue infections and is characterized by predictable dose-proportional exposure in adults.
Parent: Tedizolid
Parent: Tedizolid
![2-(2-methyltetrazol-5-yl)-5-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]Pyridine](https://veeprho.com/wp-content/uploads/2026/02/2-2-methyltetrazol-5-yl-5-6-2-methyltetrazol-5-ylpyridin-3-ylPyridine-2095840-91-6-VE0027754-fd11.png "2-(2-methyltetrazol-5-yl)-5-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]Pyridine")
Parent: Tedizolid
Typical API specification windows for tedizolid phosphate control assay purity and related substances to meet ICH guidance: assay commonly not less than 98.0 percent, any single specified related compound typically limited to 0.30 percent or less, any unspecified impurity limited to 0.10 percent or less, and total impurities typically limited to 0.50 percent or less; oxidative impurities are often limited to 0.05 percent or less and residual solvents and inorganic phosphate are controlled per respective ICH limits. Known related compounds and degradants monitored include the des-phosphorylated active tedizolid (commonly controlled to ≤0.30 percent in prodrug lots), O-dealkylated metabolites and hydrolysis products (commonly ≤0.20 percent), N-oxide species (commonly ≤0.10 percent), and dimeric or polymeric impurities (commonly ≤0.10 percent); actual specification limits vary by manufacturer and regulatory filing and should be verified against the product master file or finished product specification.
Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram positive pathogens and is used in both inpatient and outpatient settings via IV or oral administration; use should follow susceptibility data, approved labeling and local guidelines.
Both are oxazolidinone antibiotics that inhibit protein synthesis, but tedizolid has higher in vitro potency against many Gram positive pathogens, is dosed once daily, and was approved for a shorter treatment course compared with linezolid; clinical studies suggest a lower incidence of certain short-term adverse effects such as myelosuppression with tedizolid, and pharmacodynamic and drug interaction profiles differ, so choice depends on clinical scenario, susceptibility, and patient factors.
Tedizolid binds to the 50S ribosomal subunit at the peptidyl transferase center, preventing formation of the initiation complex for protein synthesis and thereby inhibiting bacterial growth.
Cost varies widely by country, payer, dosage form, pack size and whether brand or generic product is available; branded tedizolid (Sivextro) is typically priced higher than many older agents, and patients should consult local pharmacies, insurers or hospital formularies for current pricing and coverage information.
